Related Experiment Video
Updated: Sep 20, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade
Jessica B Foster1,2, Peter J Madsen3,4, Kyra Harvey2
1Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Background:
Diffuse midline glioma (DMG) and high-grade glioma are devastating pediatric central nervous system tumors that remain incurable. Recent chimeric antigen receptor (CAR) T cell studies have shown proof of concept and early signs of efficacy against DMG targeting GD2. Prior work and ongoing clinical trials have focused on using viral vectors to create permanent CAR T cells. However, virally transduced GD2-directed CAR T cells have shown significant neurotoxicity in both preclinical models and human trials.
Methods:
We evaluated transient CAR T cells targeting GD2 created with mRNA, assessing for efficacy and safety in cell line, organoid, and in vivo xenograft models with repetitive intratumoral dosing.
Results:
We show that mRNA GD2-directed CAR T cells are active against both cell lines and organoid models of DMG and high-grade glioma in vitro. Cytotoxicity consistently abates over 9 days, highlighting the potential to avoid toxicity from persistent T cell activity. In both pontine and thalamic DMG xenograft models, repeated doses of mRNA GD2-directed CAR T cells were titrated down to maintain therapeutic effects without causing neurologic toxicity.
Conclusions:
Our results demonstrate the utility of transient mRNA CAR T cells delivered intratumorally to provide effective tumor killing with a defined half-life, allowing for modulation of the dose and potential side effects. We anticipate this study will expand the use of CAR T cell therapy for DMG and other central nervous system tumors and non-malignant disorders, where concern for toxicity from permanently expressing CAR T cells may hinder development.
Insights
Transient mRNA CAR T cells targeting GD2 show promise for treating pediatric brain tumors like diffuse midline glioma (DMG). This approach offers effective tumor killing with a controlled duration, potentially reducing neurotoxicity seen with permanent CAR T cells.
Area of Science:
- Oncology
- Immunotherapy
- Pediatric Neuro-oncology
Background:
- Diffuse midline glioma (DMG) and high-grade glioma are aggressive pediatric brain tumors with poor prognoses.
- Current chimeric antigen receptor (CAR) T cell therapies targeting GD2 show efficacy but face challenges with neurotoxicity due to permanent T cell activity.
- Viral vector-based CAR T cell generation is a common method, but associated toxicities necessitate alternative strategies.
Purpose of the Study:
- To evaluate the efficacy and safety of transient CAR T cells generated with mRNA for treating pediatric central nervous system tumors.
- To assess the potential of mRNA CAR T cells to mitigate neurotoxicity associated with persistent CAR T cell activity.
Main Methods:
- Transient CAR T cells targeting GD2 were created using mRNA technology.
- Efficacy and safety were evaluated in cell line, organoid, and in vivo xenograft models of DMG.
- Repetitive intratumoral dosing strategies were employed and optimized.
Main Results:
- mRNA GD2-directed CAR T cells demonstrated in vitro activity against DMG and high-grade glioma cell lines and organoids.
- Cytotoxicity of mRNA CAR T cells naturally decreased over approximately 9 days, suggesting a self-limiting effect.
- In vivo studies showed that repeated, titrated doses of mRNA CAR T cells achieved therapeutic effects in pontine and thalamic DMG xenograft models without inducing neurologic toxicity.
Conclusions:
- Transient mRNA CAR T cells offer a viable strategy for effective, intratumorally delivered tumor killing with a defined therapeutic window.
- This approach allows for dose modulation and potential side effect management, addressing concerns of toxicity from permanent CAR T cells.
- mRNA CAR T cell therapy holds potential for expanding treatment options for DMG, other CNS tumors, and non-malignant disorders where CAR T cell toxicity is a concern.
More Related Videos
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
05:22Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
Published on: February 24, 2023